{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:01:42Z","timestamp":1789016502340,"version":"build-2803163510"},"reference-count":47,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CMAR"],"DOI":"10.2147\/cmar.s381493","type":"journal-article","created":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T05:17:26Z","timestamp":1678771046000},"page":"257-264","source":"Crossref","is-referenced-by-count":9,"title":["Targeted Treatment of Relapsed or Refractory Follicular Lymphoma: Focus on the Therapeutic Potential of Mosunetuzumab"],"prefix":"10.2147","volume":"Volume 15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7764-4336","authenticated-orcid":true,"given":"Paolo","family":"Lopedote","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazyar","family":"Shadman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,3]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.hoc.2020.02.001","volume":"34","author":"Cerhan","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.ijrobp.2005.08.010","volume":"64","author":"Guadagnolo","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1182\/blood-2018-04-843540","volume":"133","author":"Brady","year":"2019","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3324\/haematol.2021.278717","volume":"107","author":"Qualls","year":"2022","journal-title":"Haematologica"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/bjh.15708","volume":"184","author":"Rivas-Delgado","year":"2019","journal-title":"Br J Haematol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e289","DOI":"10.1016\/S2352-3026(22)00033-3","volume":"9","author":"Casulo","year":"2022","journal-title":"Lancet Haematol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/bjh.15149","volume":"184","author":"Link","year":"2019","journal-title":"Br J Haematol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"Casulo","year":"2015","journal-title":"JCO"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/cam4.1918","volume":"8","author":"Lansigan","year":"2019","journal-title":"Cancer Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1182\/blood.2020010263","volume":"139","author":"Casulo","year":"2022","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"E117","DOI":"10.1002\/ajh.25411","volume":"94","author":"Smith","year":"2019","journal-title":"Am J Hematol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1080\/17474086.2022.2044778","volume":"15","author":"Perrone","year":"2022","journal-title":"Expert Rev Hematol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1182\/blood.V70.5.1316.1316","volume":"70","author":"Loken","year":"1987","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"287ra70","DOI":"10.1126\/scitranslmed.aaa4802","volume":"7","author":"Sun","year":"2015","journal-title":"Sci Transl Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s40262-016-0405-4","volume":"55","author":"Zhu","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/protein\/9.7.617","volume":"9","author":"Ridgway","year":"1996","journal-title":"Protein Eng Design Select"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/nbt.2621","volume":"31","author":"Spiess","year":"2013","journal-title":"Nat Biotechnol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/cts.12535","volume":"11","author":"Ferl","year":"2018","journal-title":"Clin Transl Sci"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1200\/JCO.21.00931","volume":"40","author":"Budde","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41540-020-00145-7","volume":"6","author":"Hosseini","year":"2020","journal-title":"NPJ Syst Biol Appl"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Bartlett N. Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed\/refractory follicular lymphoma who received \u22652 prior therapies: updated results from a pivotal phase II study. ASH; 2022. Available from: https:\/\/ash.confex.com\/ash\/2022\/webprogram\/Paper157691.html. Accessed December 1, 2022.","DOI":"10.1182\/blood-2022-157691"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"S09","DOI":"10.1158\/1557-3265.COVID-19-21-S09-02","volume":"27","author":"Lamure","year":"2021","journal-title":"Clin Cancer Res"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/acr2.11386","volume":"4","author":"Patel","year":"2021","journal-title":"ACR Open Rheumatol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1093\/cid\/ciab700","volume":"74","author":"Calder\u00f3n-Parra","year":"2022","journal-title":"Clin Infect Dis"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s40265-022-01749-5","volume":"82","author":"Kang","year":"2022","journal-title":"Drugs"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1200\/JCO.18.00915","volume":"37","author":"Flinn","year":"2019","journal-title":"JCO"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1200\/JCO.20.03433","volume":"39","author":"Fowler","year":"2021","journal-title":"J Clin Oncol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/ajh.25711","volume":"95","author":"Dreyling","year":"2020","journal-title":"Am J Hematol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/S1470-2045(21)00145-5","volume":"22","author":"Matasar","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1200\/JCO.19.00010","volume":"37","author":"Leonard","year":"2019","journal-title":"JCO"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"8046","DOI":"10.1200\/JCO.2020.38.15_suppl.8046","volume":"38","author":"Andorsky","year":"2020","journal-title":"JCO"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1182\/blood-2022-166991","volume":"140","author":"Batlevi","year":"2022","journal-title":"Blood"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Budde E. Subcutaneous mosunetuzumab is active with a manageable safety profile in patients (pts) with relapsed\/refractory (R\/R) B-cell non-Hodgkin lymphomas (B-NHLs): updated results from a phase I\/II study. ASH; 2022. Available from: https:\/\/ash.confex.com\/ash\/2022\/webprogram\/Paper157729.html. Accessed December 1, 2022.","DOI":"10.1182\/blood-2022-157729"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1182\/blood-2021-145694","volume":"138","author":"Morschhauser","year":"2021","journal-title":"Blood"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"TPS7588","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS7588","volume":"40","author":"Nastoupil","year":"2022","journal-title":"JCO"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S2352-3026(19)30026-2","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00262-015-1671-y","volume":"64","author":"Osada","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/leu.2015.214","volume":"30","author":"Krupka","year":"2016","journal-title":"Leukemia"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"5384","DOI":"10.1158\/0008-5472.CAN-16-3431","volume":"77","author":"Chang","year":"2017","journal-title":"Cancer Res"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.575737","volume":"10","author":"Sam","year":"2020","journal-title":"Front Oncol"}],"container-title":["Cancer Management and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=88166","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=88166","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T05:17:30Z","timestamp":1678771050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/targeted-treatment-of-relapsed-or-refractory-follicular-lymphoma-focus-peer-reviewed-fulltext-article-CMAR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":47,"URL":"https:\/\/doi.org\/10.2147\/cmar.s381493","relation":{},"ISSN":["1179-1322"],"issn-type":[{"value":"1179-1322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3]]}}}